AbbVie and Johnson & Johnson’s Imbruvica is under increasing pressure from new in-class competitors, but the pair hopes a new combination and longer-term data could help consolidate its lead in ...
Many chronic lymphocytic leukemia (CLL) patients start out on Johnson & Johnson and AbbVie’s Imbruvica, a blockbuster that until recently had five indications in the disease. Thanks to a sixth granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback